Global Equities

Can Biotech Bounce Back?

Despite experiencing its deepest and longest drawdown on record, the biotechnology sector looks stronger than ever, says Portfolio Manager Andy Acker, thanks to accelerating innovation and valuations that have reset.

KEY TAKEAWAYS

  • Over the past year, biotechnology has been caught up in a historic sell-off, sending the sector’s stocks down by more than 50%, on average.
  • But in our view, biotech’s long-term growth drivers have not been impaired. On the contrary, a combination of scientific breakthroughs and robust funding are expected to lift sales by an average of 9% annually through 2026.
  • At the same time, the S&P Biotech Sector trades at half its long-term average, which could set up the sector for a strong recovery.

KEY TAKEAWAYS

  • Over the past year, biotechnology has been caught up in a historic sell-off, sending the sector’s stocks down by more than 50%, on average.
  • But in our view, biotech’s long-term growth drivers have not been impaired. On the contrary, a combination of scientific breakthroughs and robust funding are expected to lift sales by an average of 9% annually through 2026.
  • At the same time, the S&P Biotech Sector trades at half its long-term average, which could set up the sector for a strong recovery.

While global equity markets have been in retreat since the beginning of 2022, for the biotechnology sector, the selling has been going on for much longer. Since hitting a peak on 8 February 2021, the SPDR® S&P® Biotech ETF (XBI), a widely used industry benchmark, has declined by more than 50% and underperformed the S&P 500® Index by over 60% – representing the XBI’s longest contraction on record (270+ trading days), as well as its deepest on both an absolute and relative basis.1

It’s easy to be discouraged by this performance, but we don’t believe the long-term outlook for biotech has become impaired. On the contrary, with valuations compressed and innovation in the sector accelerating, we’d argue the case for biotech has only grown stronger.

Short-Term Setbacks, Long-Term Value

A number of reasons have been cited for biotech’s recent rout. For one, it followed a frothy initial public offering (IPO) market, fueled by monetary stimulus and enthusiasm for the industry’s historic COVID-19 response, lifting valuations of early-stage companies. It was impacted by a renewed push for drug-pricing reform in the U.S. and the absence of a permanent commissioner at the Food and Drug Administration (FDA), which may have contributed to unexpected regulatory decisions. Finally, the prospect of rising interest rates drove a rotation out of longer-duration assets, including biotech.

We believe many of the sector’s headwinds are showing signs of abating. Proposals that would allow the U.S. government to “negotiate” drug prices have been scaled back and, in their current form, would affect only a small subset of medicines near the end of exclusivity periods.2 The passing of legislation could also remove an overhang of uncertainty for the sector. The FDA has kept up a rapid pace of approvals – 50 new drugs in 2021, on par with the elevated rate of recent years – even before a permanent commissioner was confirmed in early 2022.3 And studies show little correlation between biotech returns and interest rates. In fact, from 2000 to 2021, biotech stocks saw gains in six out of the nine years when 10-year U.S. Treasury yields rose.4

The IPO boom that occurred in biotech in 2020 and 2021 has stalled amid market volatility and a shift to tighter monetary policy. Some reckoning was likely due: Over the past two years, private companies were often completing IPOs just months after the last private transaction, compared with a more typical one-year time frame, all while fetching premiums of 50% to 100% or more. Further, a growing percentage of firms were going public in the early stages of their pipeline development, raising risks in development and the timeline to profitability for investors.5

The IPO freeze could thaw when market volatility subsides and the path of rate hikes becomes clearer. In the meantime, there’s reason to believe many areas of the sector have become oversold. As of early 2022, a remarkable 16% of U.S.-listed biotechs traded below the level of cash on their balance sheets, more than during the 2002 and 2008 equity bear markets (8% and 11%, respectively).6 And by the end of February, valuations for large-cap biotechs sat well under their long-term average, as well as the average for the broader equity market (Exhibit 1).

Exhibit 1: Biotech Valuations Fall

Biotech Valuations Fall

Source: Bloomberg, from 30 September 1992 to 28 February 2022. The S&P Biotech Sector is composed of the large-cap biotechs in the S&P 500 Index. Forward Price-to-Earnings (P/E) Ratio measures share price compared to estimated future earnings per share for a stock or stocks in a portfolio.

Innovation Drives Growth

Even as biotech stocks have sold off, the sector’s innovation has continued to advance. Last year, more than half of drugs approved by the FDA were considered first-in-class, meaning the medicines had mechanisms of action different from those of existing therapies. Nearly three-quarters (74%) used one or more expedited development and review methods, available for drugs that have the potential to significantly advance the standard of medical care.7

Importantly, the drug pipeline is expanding. Globally, more than 6,000 medicines are actively under development, up 68% from 2016, according to the IQVIA Institute.8 Funding has been ample: In 2020, biotech and pharma saw US$27 billion in venture capital deal activity, followed by US$38 billion in 2021.9 For its part, large-cap biopharma spent a record US$133 billion on research and development last year, up 44% from 2016.10 Still, small- and mid-cap biotechs are responsible for the majority of molecules in the pipeline today, while large-cap companies face a looming patent cliff for many top-selling drugs. Consequently, it’s likely that over the coming years these industry giants, sitting on large cash reserves, will seek to replenish product portfolios through mergers and acquisitions (M&A) or strategic partnerships. Indeed, in 2022, a cohort of 18 pharma companies are estimated to have roughly US$1.7 trillion of total funding available for deal-making, including more than US$500 billion in cash.11

Positioning for Recovery

It’s anyone’s guess what will spark a rebound in biotech, whether it’s a pickup in M&A or clarity on drug-pricing reform or something else. But we do know that after the bottom of the last 11 drawdowns of at least 20%, the XBI has delivered a median return of 50% over the following 12 months.12 In addition, over the long term, returns for large-cap biotechs have historically been correlated with drug revenues. With health care demand growing and pharma pricing remaining steady – particularly as more medicines revolutionize the standard of care – revenues are projected to rise by a compound annual growth rate of 9% from 2020 to 2026 (Exhibit 2).

Exhibit 2: Nasdaq Biotechnology Index vs. Aggregate Product Revenue, 2000-2026E

Nasdaq Biotechnology Index vs. Aggregate Product Revenue, 2000-2026E

Source: Cowen and Company, as of 25 February 2022. Data from 31 December 1999 through 31 December 2026.
Note: Revenue is an aggregate of actual and estimated figures for 65 companies representative of the biotech sector. The Nasdaq Biotechnology Index is a stock market index made up of securities of Nasdaq-listed companies classified according to the Industry Classification Benchmark as either the biotechnology or the pharmaceutical industry. Red bars = estimated.

As we navigate this challenging period for biotech, we recognize that some companies may have an easier time coming through the current market environment than others. Firms with meaningful revenues/earnings, lower multiples and/or near-term pipeline catalysts could be better positioned than earlier-stage, less-liquid companies. Strong balance sheets can also help support valuations. Still, over the long term, we remain as positive as ever about the sector’s growth potential and believe the current drawdown – like the many that have come before it – will one day give way to a recovery.

Footnotes

1 Bloomberg, Janus Henderson Investors. Current drawdown data from 8 February 2021 to 14 March 2022. Data for other periods are from 27 February 2006 to 16 March 2020 and reflect declines of 20% or more in the SPDR S&P Biotech ETF (XBI). XBI is designed to correspond to the performance of a modified equal weighting of the S&P Biotechnology Select IndustryTM Index, with an inception date of 31 January 2006.
2 Kaiser Family Foundation, Simulating the Impact of the Drug Price Negotiation Proposal in the Build Back Better Act, 27 January 2022.
3 Food and Drug Administration, as of 31 December 2021.
4 Cowen and Company, This Biotech Bear Market Too Shall Pass, 25 February 2022.
5 Janus Henderson Investors, as of 31 December 2021.
6 BioCentury, Weathering one of biotech’s worst bear markets, 4 February 2022.
7 Food and Drug Administration, Advancing Health Through Innovation: New Drug Therapy Approvals 2021, January 2022.
8 IQVIA, Global Trends in R&D: Overview through 2021, February 2022.
9 Q4 2021 PitchBook-NVCA Venture Monitor, as of 31 December 2021.
10 IQVIA, Global Trends in R&D: Overview through 2021, February 2022. Data based on 15 largest pharmaceutical companies.
11 SVB Leerink, Big Biopharma Will Have $500Bn in Gross Cash to Deploy YE22 - Get Set for M&A, December 2021.
12 Bloomberg, Janus Henderson Investors. Data from 27 February 2006 to 16 March 2020 and reflect periods where the SPDR S&P Biotech ETF (XBI) experienced a price decline of 20% or more.

Read more on these topics

These are the views of the author at the time of publication and may differ from the views of other individuals/teams at Janus Henderson Investors. Any securities, funds, sectors and indices mentioned within this article do not constitute or form part of any offer or solicitation to buy or sell them.

 

Past performance does not predict future returns. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.

 

The information in this article does not qualify as an investment recommendation.

 

Marketing Communication.

 

Glossary

 

 

 

Important information

Please read the following important information regarding funds related to this article.

Janus Henderson Capital Funds Plc is a UCITS established under Irish law, with segregated liability between funds. Investors are warned that they should only make their investments based on the most recent Prospectus which contains information about fees, expenses and risks, which is available from all distributors and paying/facilities agents, it should be read carefully. This is a marketing communication. Please refer to the prospectus of the UCITS and to the KIID before making any final investment decisions. The rate of return may vary and the principal value of an investment will fluctuate due to market and foreign exchange movements. Shares, if redeemed, may be worth more or less than their original cost. This is not a solicitation for the sale of shares and nothing herein is intended to amount to investment advice. Janus Henderson Investors Europe S.A. may decide to terminate the marketing arrangements of this Collective Investment Scheme in accordance with the appropriate regulation.
    Specific risks
  • Shares/Units can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result.
  • Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses.
  • If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified.
  • The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events.
  • The Fund may use derivatives towards the aim of achieving its investment objective. This can result in 'leverage', which can magnify an investment outcome and gains or losses to the Fund may be greater than the cost of the derivative. Derivatives also introduce other risks, in particular, that a derivative counterparty may not meet its contractual obligations.
  • If the Fund holds assets in currencies other than the base currency of the Fund or you invest in a share/unit class of a different currency to the Fund (unless 'hedged'), the value of your investment may be impacted by changes in exchange rates.
  • When the Fund, or a hedged share/unit class, seeks to mitigate exchange rate movements of a currency relative to the base currency, the hedging strategy itself may create a positive or negative impact to the value of the Fund due to differences in short-term interest rates between the currencies.
  • Securities within the Fund could become hard to value or to sell at a desired time and price, especially in extreme market conditions when asset prices may be falling, increasing the risk of investment losses.
  • The Fund could lose money if a counterparty with which the Fund trades becomes unwilling or unable to meet its obligations, or as a result of failure or delay in operational processes or the failure of a third party provider.